AcelRx, a biotech developing a Phase 3 treatment for acute post-operative pain, will see its quiet period end on Tuesday, March 22. On February 10, the company raised $40 million by offering 8 million shares at $5, below the range of $12 to $14. Piper Jaffray acted as lead manager on the deal.
